143 related articles for article (PubMed ID: 28456995)
1. Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome.
Kanagal-Shamanna R; Hidalgo Lopez JE; Milton DR; Kim HR; Zhao C; Zuo Z; Janania Martinez M; Stingo F; Lee J; Luthra R; Jabbour EJ; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
Am J Hematol; 2017 Aug; 92(8):E168-E171. PubMed ID: 28456995
[No Abstract] [Full Text] [Related]
2. Validation of the WHO 2016 proposals for Myelodysplastic syndromes patients with the presence of ring sideroblasts but without excess blasts.
Li Y; Cui R; Qin T; Xu Z; Zhang Y; Cai W; Cui W; Liu J; Li B; Xiao Z
Br J Haematol; 2017 Sep; 178(5):813-816. PubMed ID: 27292319
[No Abstract] [Full Text] [Related]
3. Myelodysplastic Syndrome Updated.
Hasserjian RP
Pathobiology; 2019; 86(1):7-13. PubMed ID: 30041243
[TBL] [Abstract][Full Text] [Related]
4. New Subtype Proposed for Myelodysplastic Syndrome.
Am J Med Genet A; 2020 Aug; 182(8):1854-1855. PubMed ID: 33043582
[No Abstract] [Full Text] [Related]
5. Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q).
Tefferi A; Idossa D; Lasho TL; Mudireddy M; Finke C; Shah S; Nicolosi M; Patnaik MM; Pardanani A; Gangat N; Hanson CA; Ketterling RP
Blood Cancer J; 2017 Dec; 7(12):658. PubMed ID: 29249799
[No Abstract] [Full Text] [Related]
6. Who is WHO in myelodysplastic syndromes? Clinical implications of the WHO classification.
Komrokji RS; Bennett JM
Curr Hematol Malig Rep; 2006 Mar; 1(1):9-15. PubMed ID: 20425325
[TBL] [Abstract][Full Text] [Related]
7. The Molecular Pathology of Myelodysplastic Syndrome.
Haferlach T
Pathobiology; 2019; 86(1):24-29. PubMed ID: 29791902
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System.
van Spronsen MF; Ossenkoppele GJ; Westers TM; van de Loosdrecht AA
Eur J Cancer; 2016 Mar; 56():10-20. PubMed ID: 26798967
[TBL] [Abstract][Full Text] [Related]
9. Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes.
Komrokji R; Volpe V; Chan O; Al Ali N; Swoboda D; Kuykendall A; Padron E; Sallman DA
Blood; 2021 Sep; 138(11):989-992. PubMed ID: 34036300
[No Abstract] [Full Text] [Related]
10. Myelodysplastic syndromes classification and risk stratification.
Komrokji RS; Zhang L; Bennett JM
Hematol Oncol Clin North Am; 2010 Apr; 24(2):443-57. PubMed ID: 20359636
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of myelodysplasia-related changes according to the WHO classification among ELN-intermediate-risk AML patients.
Devillier R; Gelsi-Boyer V; Murati A; Prebet T; Rey J; Etienne A; D'Incan E; Charbonnier A; Blaise D; Mozziconacci MJ; Vey N
Am J Hematol; 2015 Jan; 90(1):E22-4. PubMed ID: 25219760
[No Abstract] [Full Text] [Related]
12. A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals.
Cabello AI; Collado R; Ruiz MA; Martínez J; Navarro I; Ferrer R; Sosa AM; Carbonell F
Leuk Res; 2005 Apr; 29(4):365-70. PubMed ID: 15725469
[TBL] [Abstract][Full Text] [Related]
13. MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations.
Stengel A; Kern W; Meggendorfer M; Haferlach T; Haferlach C
Leukemia; 2017 Sep; 31(9):1995-1997. PubMed ID: 28592886
[No Abstract] [Full Text] [Related]
14. WPSS versus simplified myelodysplastic syndrome risk score: Which is the best tool for prediction of survival in myelodysplastic patients?
Breccia M; Cannella L; Stefanizzi C; Latagliata R; Fama A; Santopietro M; Alimena G
Leuk Res; 2009 Jul; 33(7):e93-4. PubMed ID: 19070364
[No Abstract] [Full Text] [Related]
15. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
Geyer JT; Verma S; Mathew S; Wang YL; Racchumi J; Espinal-Witter R; Subramaniyam S; Knowles DM; Orazi A
Hum Pathol; 2013 Mar; 44(3):346-56. PubMed ID: 22995330
[TBL] [Abstract][Full Text] [Related]
16. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification.
Verburgh E; Achten R; Louw VJ; Brusselmans C; Delforge M; Boogaerts M; Hagemeijer A; Vandenberghe P; Verhoef G
Leukemia; 2007 Apr; 21(4):668-77. PubMed ID: 17301818
[TBL] [Abstract][Full Text] [Related]
17. Reclassifying myelodysplastic syndromes: what's where in the new WHO and why.
Arber DA; Hasserjian RP
Hematology Am Soc Hematol Educ Program; 2015; 2015():294-8. PubMed ID: 26637736
[TBL] [Abstract][Full Text] [Related]
18. [Efficiency of cyclosporin A therapy in patients with myelodysplastic syndrome].
Kokhno AV; Parovichnikova EN; Mikhaĭlova EA; Ustinova EN; Kaplanskaia IB; Dvirnyk VN; Ol'shanskaia IuV; Domracheva EV; Savchenko VG
Ter Arkh; 2010; 82(8):48-53. PubMed ID: 20873246
[TBL] [Abstract][Full Text] [Related]
19. [WHO classification of acute myeloid leukaemia (AML) and the myelodysplastic syndrome (MDS)].
Haferlach T; Schoch C
Dtsch Med Wochenschr; 2002 Mar; 127(9):447-50. PubMed ID: 11870559
[No Abstract] [Full Text] [Related]
20. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
